New drugs for Crohn's disease! Eu approves Skyrizi: The First specific IL-23 inhibitor for Crohn's Disease!
2022-11-25
Abbvie announced that the European Commission has approved a new indication for Skyrizi, its novel anti-inflammatory IL-23 inhibitor: Skyrizi 600mg intravenous induction and 360mg subcutaneous maintenance therapy were used to treat adults with moderate to severe active Crohn's disease who were under-responsive, unresponsive, or intolerant to conventional or biological therapies. It is worth mentioning that Skyrizi is the first specific IL-23 inhibitor approved for the treatment of CD in the European Union and the United States.
